证券代码：603139 证券简称：康惠制药 公告编号：2025-036 陕西康惠制药股份有限公司 审核暨控制权拟发生变更的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 本次权益变动相关事项已通过上海证券交易所合规性审核。 本次权益变动事项尚需在中国证券登记结算有限责任公司上海分公司办 理股份过户登记手续，最终实施结果尚存在不确定性，敬请投资者注意投资风险。 一、本次权益变动基本情况 2025 年 3 月 20 日, 陕西康惠制药股份有限公司（以下简称"康惠制药"、"上 市公司"）控股股东陕西康惠控股有限公司（以下简称"康惠控股"）与嘉兴悦合 智创科技合伙企业（有限合伙）（以下简称"悦合智创"）签署《股份转让协议》, 康惠控股拟向悦合智创协议转让其持有上市公司 21,973,600 股股份（占上市公 司股份总数的 22%），转让价格为人民币 24.70 元/股。2025 年 3 月 25 日，康惠 控股与悦合智创签署《股份转让协议之补充协议》，同时康惠控股出具《关于放 弃表决权的承诺函》，承诺自《股份转 ...

Core Points - The controlling shareholder of Kanghui Pharmaceutical (603139) is transferring 21,973,600 shares, representing 22% of the total shares, to Jiaxing Yuehe Zhichuang Technology Partnership at a price of RMB 24.7 per share [1] - Following the share transfer, the controlling shareholder will change to Yuehe Zhichuang, with the actual controllers being Li Hongming and Wang Xuefang [1] - Kanghui Pharmaceutical has received confirmation from the Shanghai Stock Exchange regarding the share transfer agreement, but the final implementation is subject to registration with the China Securities Depository and Clearing Corporation [1]

证券代码：603139 证券简称：康惠制药 公告编号：2025-035 陕西康惠制药股份有限公司 关于为菩丰堂提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 被担保人名称：四川菩丰堂药业有限公司（以下简称"菩丰堂"，系公 司控股子公司四川春盛药业集团股份有限公司的全资子公司） 本次担保金额：600 万元人民币；本次担保后实际为其提供的担保余额： 1,097 万元 特别风险提示：被担保人菩丰堂药业的资产负债率超过 70%，请广大投 资者充分关注担保风险。 一、担保情况概述 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日及 2025 年 5 月 20 日，召开第五届董事会第十七次会议、第五届监事会第十四次会议及 2024 年年度股东大会，审议通过《关于 2025 年度预计为控股子公司提供担保的 议案》，同意公司为控股子公司在金融机构申请的综合授信额度提供不超过 19,800 万元的连带责任保证，其中，同意为菩丰堂在金融机构申请的授信，提 供不超过 1,100 万元 ...

Summary of Key Points Core Viewpoint - The company has provided a guarantee of 6 million RMB for its subsidiary, Sichuan Pufengtang Pharmaceutical Co., Ltd, to secure a loan from China Bank, with a total guarantee balance of 10.97 million RMB remaining [1][2][3]. Group 1: Guarantee Details - The guarantee amount provided by the company is 6 million RMB, with a total guarantee balance of 10.97 million RMB after this transaction [1][3]. - The company has a counter-guarantee agreement with other shareholders of Pufengtang, covering 49% of the guaranteed debt [3][6]. - The guarantee is structured as a joint liability guarantee, covering principal, interest, penalties, and other related costs [5][6]. Group 2: Financial Status of the Guaranteed Entity - Sichuan Pufengtang has total assets of approximately 42.28 million RMB and total liabilities of about 45.54 million RMB, resulting in a negative net asset of approximately -3.25 million RMB [4][5]. - The company's revenue for the last fiscal year was approximately 2.28 million RMB, with a net loss of about -1.70 million RMB [5]. Group 3: Board's Opinion and Justification - The board of directors believes that the guarantee is necessary for the subsidiary's financing needs and aligns with the company's strategic interests, posing no adverse effects on the company's operations [6][7]. - The board approved the guarantee with unanimous support, indicating confidence in the subsidiary's financial management and risk control [7][8].

Group 1 - The hair medical concept sector declined by 0.99%, ranking among the top declines in concept sectors, with stocks like Kanghui Pharmaceutical and *ST Jinbi hitting the limit down [1] - Within the sector, major decliners included Aoyang Health and Tainkang, while stocks that increased included Shuiyang Co., Yisheng Pharmaceutical, and Nengte Technology, with respective increases of 4.13%, 1.81%, and 1.58% [1] - The hair medical concept sector experienced a net outflow of 228 million yuan from main funds, with 14 stocks seeing net outflows, and 6 stocks with outflows exceeding 10 million yuan [2] Group 2 - The top net outflow stocks included Tainkang with a net outflow of 63.36 million yuan, followed by *ST Jinbi and Aoyang Health with outflows of 59.14 million yuan and 57.88 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Xianju Pharmaceutical, Yisheng Pharmaceutical, and Guoyao Modern, with net inflows of 6.84 million yuan, 5.62 million yuan, and 3.33 million yuan respectively [3] - The trading volume for Tainkang was 5.55%, while *ST Jinbi had a turnover rate of 21.44%, indicating significant trading activity in these stocks despite the declines [2]

暗盘资金一眼洞悉庄家意图>> 中药板块短线走低，康惠制药（603139）跌停，恩威医药（301331）、万邦德（002082）、沃华医药 （002107）、康缘药业（600557）、珍宝岛（603567）等跟跌。 ...

Market Overview - The A-share market experienced a decline due to overseas geopolitical risks, with major indices closing in the red. The Shanghai Composite Index fell by 0.72%, the Shenzhen Component dropped by 1.15%, and the ChiNext Index decreased by 1.14% [2][3] - The total market turnover reached 936.17 billion yuan, showing a significant increase compared to the previous day, with only 865 stocks rising against 4,460 stocks declining [4][5] Sector Performance - The energy equipment, shipping, oil and gas, aerospace and defense, and precious metals sectors saw gains, while the consumer sector faced widespread declines, particularly in leisure goods, soft drinks, cultural media, and tourism [5][6] - The energy equipment sector rose by 4.61%, shipping by 3.50%, oil and gas by 1.83%, and aerospace and defense by 1.46% [6] Notable Stocks - In the defense and aerospace sector, stocks such as Jieqiang Equipment and Beifang Changlong hit the daily limit up of 20%, while Chenxi Aviation rose nearly 17% [9][10] - The shipping index strengthened, with stocks like Guohang Ocean rising over 14% and Phoenix Shipping hitting the daily limit up [11][12] Consumer Sector Decline - The consumer sector saw a collective pullback, with notable declines in stocks related to the "grain economy" concept, such as Chuangyuan Shares dropping over 11% [13][14] - The medical beauty index also fell, with stocks like Shuiyang Shares and Kelaibao experiencing significant declines [15] Specific Stock Movements - Kanghui Pharmaceutical and ST United both exhibited "Heaven and Earth" patterns, with Kanghui opening at a limit up before dropping to a low of 24.71 yuan per share, closing at 25.5 yuan, down 7.1% [16]

Core Viewpoint - The stock of Kanghui Pharmaceutical experienced a significant drop, hitting the daily limit down, with a trading volume exceeding 150 million yuan [1] Group 1 - Kanghui Pharmaceutical's stock price fell to the daily limit, indicating a strong negative market reaction [1] - The trading volume for Kanghui Pharmaceutical surpassed 150 million yuan, reflecting heightened trading activity and investor interest [1]

证券代码：603139 证券简称：康惠制药 公告编号：2025-034 陕西康惠制药股份有限公司 关于股票交易风险提示的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 陕西康惠制药股份有限公司（以下简称"公司"）股票于 2025 年 6 月 9 日、 6 月 10 日、6 月 11 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%，根 据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。公司 已于 2025 年 6 月 12 日在上海证券交易所网站及指定信息披露媒体披露了《股票 交易异常波动公告》（公告编号：2025-032）。 2025 年 6 月 12 日，公司股票再次涨停。鉴于公司股票连续多日涨幅较大， 敬请广大投资者注意交易风险，理性决策，审慎投资。公司现对股票交易提示说 明如下： 一、生产经营情况 重大事件。 四、重大事项存在不确定性的风险 公司控制权拟发生变更，具体内容详见公司于 2025 年 3 月 21 日、3 月 26 日在上海证券交易所网站（www.sse.com.cn）披露的《康惠 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-033 陕西康惠制药股份有限公司 关于持股 5%以上股东协议转让公司部分股份 完成过户登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、股份转让相关事项概述 响投资合伙企业（有限合伙）（以下简称"创响投资"）签订了《关于陕西康惠 制药股份有限公司之股份转让协议》，赛乐仙拟将其持有的公司无限售条件流通 股 5,992,800 股（占公司总股本的 6%）转让给创响投资。 本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发生变 更 （ 具 体 内 容 详 见 公 司 于 2025 年 4 月 22 日 在 上 海 证 券 交 易 所 网 站 http://www.sse.com.cn 披露的 2025-016 号公告及相关股东披露的《简式权益变动 报告书》）。 二、股份转让进展暨过户情况 本次权益变动已通过上海证券交易所协议转让合规确认，并于 2025 年 6 月 创响投资受让赛乐仙持有的公司无限售条件流通股 5,992,800 股股份过户登记 ...